Genocea Reports Fourth Quarter and Year-End 2015 Financial Results

- Multiple 2016 clinical milestones for GEN-003 for genital herpes anticipated -
- Cancer vaccine strategy targeting generation of first clinical candidate in 2017 -

CAMBRIDGE, Mass., Feb. 11, 2016  -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported corporate highlights and financial results for the fourth quarter and year ended December 31, 2015.

"2015 was another year of important progress for our lead product candidate, GEN-003 for genital herpes, and our ATLAS^TM T cell target discovery platform. In October, we demonstrated significant and durable Phase 2 efficacy for GEN-003, potentially positioning it to become the cornerstone treatment for the millions of people who suffer from genital herpes infections. 2016 will also be a rich year for GEN-003 clinical milestones with 12-month durability data from the ongoing Phase 2 trial expected later this quarter, virologic and clinical efficacy data from a Phase 2b study expected in the middle and second half of 2016, respectively, and an end-of-Phase 2 meeting with the FDA anticipated in the fourth quarter,” said Chip Clark, president and chief executive officer of Genocea.

Quarterly Report for Period Ending 2015-12-31

SHELTON, Conn., Feb. 10, 2016  -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), filed its quarterly report in a timely manner with the Securities and Exchange Commission on Tuesday, February 9th. The submission can be downloaded from the SEC website at http://www.sec.gov/Archives/edgar/data/1379006/000114420416079966/v429785_10q.htm.

NanoViricides reported that it had approximately $28.3 Million (M) of current assets plus restricted cash (cash, cash equivalents, collateral advance, prepaid expenses, and security deposits) as of December 31, 2015, the end of the reporting period. The net cash used in operating activities during this quarter was approximately $1.22M. Shareholder equity stood at approximately $28.38M for the quarter (unaudited figures). The Company does not anticipate any major capital expenditures in the near future.

The Company estimates that the cash in hand is sufficient to enable us to perform initial human clinical trials of at least one of our drug candidates, as well as to advance at least one more drug candidate drug candidate towards initial human clinical trials. The Company's expenditures during the reported period were on track with this expectation.

Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study

HASBROUCK HEIGHTS, N.J., Feb. 09, 2016 -- Nymox Pharmaceutical Corporation (NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.

The clinical trial commenced in February 2012 at 28 U.S. investigational clinical trial sites and enrolled 147 patients with low grade localized (T1c) prostate cancer. The study lasted 40 months overall from the first patient randomized to the last patient 18 month endpoints.